ライフサイエンスコーパス: epithelial ovarian cancer

1 significantly associated with lower odds of epithelial ovarian cancer.

2 sing strategy for targeting ALDH activity in epithelial ovarian cancer.

3 metastasis in an established mouse model for epithelial ovarian cancer.

4 s is a validated clinical target in advanced epithelial ovarian cancer.

5 7S, and p.L517P), not reported previously in epithelial ovarian cancer.

6 val in a preclinical model of advanced stage epithelial ovarian cancer.

7 enesis is a valid target in the treatment of epithelial ovarian cancer.

8 ar cell (rs11651755 OR=0.77, P=1.6 x 10(-8)) epithelial ovarian cancer.

9 aluation, and improved imaging strategies in epithelial ovarian cancer.

10 ic efficacy of paclitaxel in mouse models of epithelial ovarian cancer.

11 r women with newly diagnosed, advanced-stage epithelial ovarian cancer.

12 s in tumor-bearing mice and in patients with epithelial ovarian cancer.

13 o follow women during or after treatment for epithelial ovarian cancer.

14 by about 4 months in patients with advanced epithelial ovarian cancer.

15 r of angiogenesis and disease progression in epithelial ovarian cancer.

16 an initial stage in a screening strategy for epithelial ovarian cancer.

17 n and has single-agent activity in recurrent epithelial ovarian cancer.

18 ermine the potential role of CD133+ cells in epithelial ovarian cancer.

19 er new biomarkers and therapeutic targets in epithelial ovarian cancer.

20 al regulatory protein often downregulated in epithelial ovarian cancer.

21 ukemia, contribute to the pathophysiology of epithelial ovarian cancer.

22 genesis can be effective in the treatment of epithelial ovarian cancer.

23 (OR, 0.98 [95% CI, 0.91-1.05]; P = .55) with epithelial ovarian cancer.

24 an important priority for the prevention of epithelial ovarian cancer.

25 in a predominantly European population with epithelial ovarian cancer.

26 zed biospecimens from 20 human patients with epithelial ovarian cancer.

27 standard-of-care first-line chemotherapy for epithelial ovarian cancer.

28 tatic pancreatic adenocarcinoma and advanced epithelial ovarian cancer.

29 ndard 3-weekly treatment among patients with epithelial ovarian cancer.

30 (FR), which is expressed on the majority of epithelial ovarian cancers.

31 oth the ovarian surface epithelium (OSE) and epithelial ovarian cancers.

32 cancer set (n=360) comprised 176 women with epithelial ovarian cancer, 115 healthy controls and 69 c

33 cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioi

34 k of overall and histotype-specific invasive epithelial ovarian cancer (22,406 cases; 40,941 controls

35 Here we explore the role of LARP1 in epithelial ovarian cancer, a disease characterized by th

36 Benth suppressed the proliferation of human epithelial ovarian cancer, A2780 and the related paclita

37 the association between PID and the risk of epithelial ovarian cancer according to tumor behavior an

38 Methods: Twelve patients with relapsed epithelial ovarian cancer, achieving a second complete o

39 otherwise healthy women with advanced-stage epithelial ovarian cancer aged 70 years or younger.

40 analysis of retrospective cohort analyses of epithelial ovarian cancer among BRCA1/2 mutation carrier

41 nd the CIMBA sample included 3887 women with epithelial ovarian cancer and 27 561 control individuals

42 1880 control women, 1135 women with invasive epithelial ovarian cancer and 321 women with borderline

43 C sample included 22 406 women with invasive epithelial ovarian cancer and 40 941 control individuals

44 2 risk factors were associated with invasive epithelial ovarian cancer and 8 of the 12 were associate

45 thway among 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaf

46 rapy fails in more than 20% of patients with epithelial ovarian cancer and about 40-50% of women who

47 The ovarian cancer set comprised women with epithelial ovarian cancer and controls (both healthy con

48 expressed between vascular cells from human epithelial ovarian cancer and healthy ovaries.

49 he PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast ca

50 stant disease after primary therapy typifies epithelial ovarian cancer and may be attributable to res

51 ave been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer

52 of alpelisib and olaparib for patients with epithelial ovarian cancer and patients with breast cance

53 of tumor samples from 395 women with primary epithelial ovarian cancer and tested whether PEA-15 expr

54 purified endothelial cells from 10 invasive epithelial ovarian cancers and 5 normal ovaries using Af

55 Here, we examined the clinical (n = 93 epithelial ovarian cancers) and biological (in vitro adh

56 F) receptor (EGFR) is frequently elevated in epithelial ovarian cancer, and E-cadherin expression is

57 let-7a-3 methylation was detected in epithelial ovarian cancer, and the expression of let-7a

58 ween olaparib and alpelisib, particularly in epithelial ovarian cancer, and warrants further investig

59 HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed epigenetic si

60 gold nanoelectrode ensemble (GNEE) to detect epithelial ovarian cancer antigen-125 (CA 125), a protei

61 menopausal women who had been diagnosed with epithelial ovarian cancer (any International Federation

62 Advanced-stage epithelial ovarian cancers are amongst the most difficul

63 n IGF2 were associated with risk of invasive epithelial ovarian cancer at P<0.05 and followed-up one

64 port a phenotypic chemosensitivity assay for epithelial ovarian cancer based on Doppler spectroscopy

65 at CD11b(+)Gr-1(+) cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stage

66 in fee-for-service Medicare, diagnosed with epithelial ovarian cancer between 1997 and 2007, and die

67 men aged 35-74 years who were diagnosed with epithelial ovarian cancer between 2002 and 2005 and 1,31

68 lial ovarian cancer (general population) and epithelial ovarian cancer (BRCA1/2 mutation carriers), m

69 red successfully as first-line treatment for epithelial ovarian cancer but does not significantly imp

70 still treated by doctors who usually manage epithelial ovarian cancer but rarely see these patients.

71 We studied miRNA deregulation in human epithelial ovarian cancer by integrative genomic approac

72 n a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using

73 V) against an invasive variant of the murine epithelial ovarian cancer cell line ID8-T.

74 or somatic H1 variants, H1.3, in the OVCAR-3 epithelial ovarian cancer cell line.

75 isolate ALDH1-bright (ALDH1(br)) cells from epithelial ovarian cancer cell lines and characterized t

76 Here, we use 10 epithelial ovarian cancer cell lines to investigate 2D m

77 CRISPR/Cas9-mediated deletion of DAB2IP in epithelial ovarian cancer cell lines upregulated express

78 tumour site of origin and histopathology of epithelial ovarian cancer cell lines.

79 asts from normal ovary and tumor samples and epithelial ovarian cancer cell lines.

80 ro and in vivo models we show that secondary epithelial ovarian cancer cells (sEOC) do not fully reac

81 eceptor and CD46 were able to trigger EMT in epithelial ovarian cancer cells and cause efficient onco

82 Metastatic epithelial ovarian cancer cells are disseminated intrape

83 quire the molecular signature of the primary epithelial ovarian cancer cells from which they are deri

84 In the current study, culture of epithelial ovarian cancer cells on three-dimensional col

85 ceptional antiproliferative behavior against epithelial ovarian cancer cells resistant to cisplatin.

86 elial-mesenchymal transition is required for epithelial ovarian cancer cells to acquire metastatic po

87 ur results indicate that OvCa429 and SKOV3ip epithelial ovarian cancer cells undergo similar morpholo

88 xerted an anti-proliferative effect on human epithelial ovarian cancer cells, A2780/WT and A2780/PTX(

89 rmation of in vitro PTX efficacy in ID8-VEGF epithelial ovarian cancer cells, in vivo studies were pe

90 using stable knockdown and overexpression in epithelial ovarian cancer cells, we show that TG2 induce

91 e mechanism of action of compound 1 in A2780 epithelial ovarian cancer cells.

92 hemotherapy in women with optimally debulked epithelial ovarian cancer confined to the abdominal cavi

93 The standard initial management of epithelial ovarian cancer consists of surgical staging,

94 Based on these findings, we assert that epithelial ovarian cancers derive from a subpopulation o

95 re setting of patients with primary invasive epithelial ovarian cancers diagnosed from January 2000 t

96 associate with risk of serous and clear cell epithelial ovarian cancer; DNA methylation and expressio

97 Despite clinical remission of epithelial ovarian cancer (EOC) after surgical resection

98 Effective targets to treat advanced epithelial ovarian cancer (EOC) and biomarkers to predic

99 ncer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most im

100 -1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most im

101 protein (PTB) and SRp20, were upregulated in epithelial ovarian cancer (EOC) and knockdown of PTB exp

102 m published studies of Myc family targets in epithelial ovarian cancer (EOC) and neuroblastoma.

103 transglutaminase 2 (TG2) is overexpressed in epithelial ovarian cancer (EOC) and promotes intraperito

104 The underlying causes of epithelial ovarian cancer (EOC) are unclear, and treatme

105 Most women are diagnosed with epithelial ovarian cancer (EOC) at advanced stage, where

106 Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germli

107 ecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in

108 is study, we report that a sub-population of epithelial ovarian cancer (EOC) cells co-expresses Lin28

109 The motility of SKOV-3 epithelial ovarian cancer (EOC) cells has been shown to

110 During tumor progression, epithelial ovarian cancer (EOC) cells undergo epithelial

111 ophosphatidic acid (LPA) levels around human epithelial ovarian cancer (EOC) cells.

112 recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2

113 Studies of the role of dietary factors in epithelial ovarian cancer (EOC) development have been li

114 itor (PARPi) sensitivity commonly coexist in epithelial ovarian cancer (EOC) due to the high prevalen

115 Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking ang

116 Epithelial ovarian cancer (EOC) has a heritable componen

117 Epithelial ovarian cancer (EOC) has poor prognosis and r

118 d validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken

119 RAD51B, RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in

120 BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population.

121 impact of the Trp53(R172H)-mutant allele on epithelial ovarian cancer (EOC) in vivo We used the Pten

122 Epithelial ovarian cancer (EOC) is a highly lethal gynec

123 Epithelial ovarian cancer (EOC) is a leading cause of ca

124 The five-year survival rate of epithelial ovarian cancer (EOC) is approximately 35-40%

125 Epithelial ovarian cancer (EOC) is characterized by an i

126 The high mortality of epithelial ovarian cancer (EOC) is mainly caused by resi

127 Epithelial ovarian cancer (EOC) is one of the most commo

128 Epithelial ovarian cancer (EOC) is the fifth leading cau

129 Epithelial ovarian cancer (EOC) is the fifth most common

130 Epithelial ovarian cancer (EOC) is the fourth leading ca

131 Epithelial ovarian cancer (EOC) is the leading cause of

132 Epithelial ovarian cancer (EOC) is the leading cause of

133 Epithelial ovarian cancer (EOC) is the most deadly gynae

134 Epithelial ovarian cancer (EOC) is the most fatal gynaec

135 Epithelial ovarian cancer (EOC) is the most lethal gynae

136 Epithelial ovarian cancer (EOC) is the most lethal gynec

137 Invasive epithelial ovarian cancer (EOC) is the most lethal gynec

138 Epithelial ovarian cancer (EOC) is the most lethal of gy

139 Epithelial ovarian cancer (EOC) metastasis occurs by exf

140 germ-line BRCA1/2 mutations in patients with epithelial ovarian cancer (EOC) on responses to first an

141 All patients diagnosed in Scotland with epithelial ovarian cancer (EOC) or primary peritoneal ca

142 Serous epithelial ovarian cancer (EOC) patients often succumb t

143 NY-ESO-1 (rF-NY-ESO-1) in 25 melanoma and 22 epithelial ovarian cancer (EOC) patients with advanced d

144 d microvesicles that play important roles in epithelial ovarian cancer (EOC) progression, as they are

145 During epithelial ovarian cancer (EOC) progression, intraperito

146 Ascites in epithelial ovarian cancer (EOC) promotes tumor developme

147 PURPOSE OF REVIEW: Management of the epithelial ovarian cancer (EOC) remains a therapeutic ch

148 Epithelial ovarian cancer (EOC) remains the most lethal

149 Epithelial ovarian cancer (EOC) remains the most lethal

150 g arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk.

151 cancer tissue microarrays and 56 additional epithelial ovarian cancer (EOC) samples.

152 Recently, we reported the isolation of the epithelial ovarian cancer (EOC) stem cells (type I/CD44+

153 ssociation studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles.

154 a common complication in the late stages of epithelial ovarian cancer (EOC) that greatly diminishes

155 egulates MAD2L2 and sensitizes HR-proficient epithelial ovarian cancer (EOC) to poly(adenosine diphos

156 in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin a

157 alyzed from all women in whom a diagnosis of epithelial ovarian cancer (EOC) was confirmed and from b

158 inverse association between hysterectomy and epithelial ovarian cancer (EOC) was considered well esta

159 The majority of women diagnosed with epithelial ovarian cancer (EOC) will be diagnosed with a

160 nt advances in the molecular pathogenesis of epithelial ovarian cancer (EOC) with new insights into t

161 rous ovarian cancer is an aggressive form of epithelial ovarian cancer (EOC), and accounts for the ma

162 variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cau

163 ne protease HtrA1 as a downregulated gene in epithelial ovarian cancer (EOC), but the functional cons

164 to correlate with prognosis in patients with epithelial ovarian cancer (EOC), but their prognostic im

165 idence of breast cancer after a diagnosis of epithelial ovarian cancer (EOC), one of the tubal/perito

166 sociated with clinical outcome in women with epithelial ovarian cancer (EOC), participants that had p

167 eles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from mul

168 have identified four susceptibility loci for epithelial ovarian cancer (EOC), with another two sugges

169 women to identify risk genetic variants for epithelial ovarian cancer (EOC).

170 taxel using an orthotopic xenograft model of epithelial ovarian cancer (EOC).

171 dentified 39 regions associated with risk of epithelial ovarian cancer (EOC).

172 of coffee and tea consumption on the risk of epithelial ovarian cancer (EOC).

173 phospholipase A(2) (iPLA(2)) is involved in epithelial ovarian cancer (EOC).

174 inical impediment to effective management of epithelial ovarian cancer (EOC).

175 py develops in the majority of patients with epithelial ovarian cancer (EOC).

176 ibutes to the development and progression of epithelial ovarian cancer (EOC).

177 needed to treat platinum-sensitive recurrent epithelial ovarian cancer (EOC).

178 t PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC).

179 r understanding of genetic susceptibility to epithelial ovarian cancer (EOC).

180 rogression in various malignancies including epithelial ovarian cancer (EOC).

181 a promising strategy for treating metastatic epithelial ovarian cancer (EOC).

182 uvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC).

183 prognosis in several solid tumors, including epithelial ovarian cancer (EOC).

184 studies posit a role for non-coding RNAs in epithelial ovarian cancer (EOC).

185 Up to 50% of epithelial ovarian cancers (EOC) display defects in the

186 s to PARP inhibitors (PARPi) in BRCA-mutated epithelial ovarian cancers (EOC), PARPi resistance remai

187 Highly aneuploid tumours are common in epithelial ovarian cancers (EOC).

188 the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC).

189 cale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in ge

190 Epithelial ovarian cancers (EOCs) often exhibit morpholo

191 library of 139 gynecologic tumors including epithelial ovarian cancers (EOCs), cervical, endometrial

192 aracterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs).

193 inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum

194 The majority of women diagnosed with epithelial ovarian cancer eventually develop recurrence,

195 C) is the most common and aggressive form of epithelial ovarian cancer, for which few targeted therap

196 of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a qua

197 v 19, 2012, we enrolled women with recurrent epithelial ovarian cancer from 32 countries.

198 Overall and histotype-specific invasive epithelial ovarian cancer (general population) and epith

199 Epithelial ovarian cancer generally presents at an advan

200 Epithelial ovarian cancer has a major heritable componen

201 The classification of epithelial ovarian cancer has been substantially revised

202 Patients with BRCA-associated epithelial ovarian cancer have improved response to plat

203 els for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number

204 Patients with epithelial ovarian cancer have the best overall survival

205 regions conferring risk of high-grade serous epithelial ovarian cancer (HGSOC).

206 rscore distinct mechanisms driving different epithelial ovarian cancer histological subtypes.

207 invasive epithelial ovarian cancer, invasive epithelial ovarian cancer histotypes, and low malignant

208 e 12 were associated with 1 or more invasive epithelial ovarian cancer histotypes.

209 Endometriosis is a risk factor for epithelial ovarian cancer; however, whether this risk ex

210 using a syngeneic orthotopic mouse model of epithelial ovarian cancer (ID8).

211 weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free surv

212 sterone sulfate were associated with risk of epithelial ovarian cancer in a nested-case control study

213 k1, Bsm1, Cdx2) were associated with risk of epithelial ovarian cancer in a retrospective case-contro

214 factor alpha receptor 2-and risk of invasive epithelial ovarian cancer in prospectively collected sam

215 nalysis of case-control analyses of invasive epithelial ovarian cancer in the Ovarian Cancer Associat

216 ic plasma metabolites (N = 420) with risk of epithelial ovarian cancer, including both borderline and

217 nd young adults aged 15 to 25 years with non-epithelial ovarian cancers, including malignant ovarian

218 alyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression.

219 and molecular factors) with risk of invasive epithelial ovarian cancer, invasive epithelial ovarian c

220 Epithelial ovarian cancer is a highly heterogeneous dise

221 Epithelial ovarian cancer is a leading cause of death in

222 Epithelial ovarian cancer is an aggressive malignancy, w

223 Epithelial ovarian cancer is composed of distinct histol

224 Although it is well known that epithelial ovarian cancer is moderately chemosensitive,

225 Epithelial ovarian cancer is the commonest cause of gyna

226 Epithelial ovarian cancer is the leading cause of death

227 Epithelial ovarian cancer is the most frequent cause of

228 Epithelial ovarian cancer is the most lethal gynecologic

229 Epithelial ovarian cancer is the most lethal gynecologic

230 rent dietary flavonoid subclasses on risk of epithelial ovarian cancer is unclear, with limited previ

231 d we observed epigenetic silencing in serous epithelial ovarian cancer, leading us to hypothesize tha

232 uggest that the major histologic subtypes of epithelial ovarian cancer may have different risk factor

233 Because of the surface epithelial origin of epithelial ovarian cancer, mucins are obvious biomolecul

234 ascites of a patient with advanced recurrent epithelial ovarian cancer (named OVASC-1).

235 hat for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and

236 ankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with folli

237 ssociated with an increased risk of invasive epithelial ovarian cancer (odds ratio [OR] per 50% highe

238 holesterol was associated with lower odds of epithelial ovarian cancer (odds ratio [OR], 0.60 [95% CI

239 intron 5 A>G (rs9909104) was associated with epithelial ovarian cancer [odds ratio (OR), 1.2; 95% con

240 ssociated with an increased risk of invasive epithelial ovarian cancer (OR per unit increase in smoki

241 ve revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of

242 Epithelial ovarian cancer (OvCa) is associated with high

243 A third of patients with epithelial ovarian cancer (OVCA) will not respond to sta

244 a role for few of these factors in invasive epithelial ovarian cancer overall and suggests distinct

245 f benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).

246 of (18)F-FES PET/CT for endocrine therapy in epithelial ovarian cancer patients is warranted.

247 Tumor samples from epithelial ovarian cancer patients were evaluated for ER

248 ne tumor ERalpha expression noninvasively in epithelial ovarian cancer patients.

249 ortisol rhythms, and facets of depression in epithelial ovarian cancer patients.

250 Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage di

251 so show its effectiveness in transferring an epithelial ovarian cancer prognostic gene signature acro

252 hat drive the development and progression of epithelial ovarian cancer remain obscure.

253 Women with BRCA-associated epithelial ovarian cancer represent a unique group who c

254 Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 7

255 oms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgi

256 in this gene differentially associates with epithelial ovarian cancer risk according to histological

257 ively map variation in HNF1B with respect to epithelial ovarian cancer risk and analyse DNA methylati

258 rious risk factors have been associated with epithelial ovarian cancer risk in observational epidemio

259 ) to examine the association between CRP and epithelial ovarian cancer risk overall, by histologic su

260 potential chemopreventive role of statins in epithelial ovarian cancer risk.

261 ulating 25(OH)D concentration in relation to epithelial ovarian cancer risk.

262 r ALDH1 on a tissue microarray containing 84 epithelial ovarian cancer samples revealed that patients

263 The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by fre

264 men with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynec

265 angiogenesis option for women with recurrent epithelial ovarian cancer should be investigated in othe

266 All women diagnosed with epithelial ovarian cancer should have germline genetic t

267 Women with epithelial ovarian cancer should have testing at the tim

268 25 responses to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as individu

269 ase III trial (GOG 172) in optimal stage III epithelial ovarian cancer showed that intravenous (IV) p

270 l therapy has been used erratically to treat epithelial ovarian cancer since the mid 1960s; however,

271 trix metalloproteinase was observed in human epithelial ovarian cancer specimens.

272 We found that epithelial-ovarian cancer stem cells (EOC stem cells) ar

273 Of the 28 patients with epithelial ovarian cancer, ten (36%) achieved a partial

274 ich have started to define biomarkers within epithelial ovarian cancers that link with hormonal respo

275 BRCA testing for all women with non-mucinous epithelial ovarian cancer, there is significant variabil

276 suppressed malignant proliferation in human epithelial ovarian cancer, thus proving to be a potentia

277 RL4 components are highly expressed in human epithelial ovarian cancer tissues.

278 ent mouse model of intraperitoneal papillary epithelial ovarian cancer to show that modulation of the

279 analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between p

280 K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors.

281 PATIENTS AND METHODS Study: participants had epithelial ovarian cancer treated with surgery followed

282 PET/CT can reliably assess ERalpha status in epithelial ovarian cancer tumors and metastases noninvas

283 th intraperitoneal alpha-particle therapy in epithelial ovarian cancer using (211)At conjugated to MX

284 nomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial ar

285 e CT images in patients with stage III or IV epithelial ovarian cancer was independently associated w

286 follow-up (1976-2004), 612 cases of invasive epithelial ovarian cancer were confirmed.

287 ge of 8.0 years of follow up, 2,681 cases of epithelial ovarian cancer were detected.

288 Additional patients with epithelial ovarian cancer were enrolled in a dose-expans

289 A total of 666 confirmed cases of epithelial ovarian cancer were identified over 2,790,986

290 2933 women with invasive epithelial ovarian cancer were included: 1742 with high-

291 eight patients with histologically confirmed epithelial ovarian cancer were observed from the date of

292 y and Obstetrics (FIGO) high-risk stage I-IV epithelial ovarian cancer were randomly allocated (1:1)

293 ion of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer were randomly assigned to grou

294 Human samples and mouse models of epithelial ovarian cancer were used to explore the under

295 illion women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous

296 ge III (incompletely resectable) or stage IV epithelial ovarian cancer who had undergone debulking su

297 patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with dru

298 ynecology stage III (n = 172) or IV (n = 31) epithelial ovarian cancer who underwent CT before primar

299 ive CT scans from patients with stage III/IV epithelial ovarian cancer who underwent primary cytoredu

300 rimary treatment most patients with advanced epithelial ovarian cancer will relapse.